相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Probing the Bioactivity-Relevant Chemical Space of Robust Reactions and Common Molecular Building Blocks
Markus Hartenfeller et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2012)
Designing the molecular future
Gisbert Schneider
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2012)
Nonlinear dimensionality reduction and mapping of compound libraries for drug discovery
Michael Reutlinger et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2012)
DRUG DISCOVERY Chemical beauty contest
Pau Leeson
NATURE (2012)
Quantifying the chemical beauty of drugs
G. Richard Bickerton et al.
NATURE CHEMISTRY (2012)
DOGS: Reaction-Driven de novo Design of Bioactive Compounds
Markus Hartenfeller et al.
PLOS COMPUTATIONAL BIOLOGY (2012)
Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000-2009
K. I. Kaitin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
PLK1 as an oncology target: current status and future potential
Campbell McInnes et al.
DRUG DISCOVERY TODAY (2011)
Drug discovery in the next decade: innovation needed ASAP
Youssef L. Bennani
DRUG DISCOVERY TODAY (2011)
Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors
Gisbert Schneider et al.
FUTURE MEDICINAL CHEMISTRY (2011)
Getting pharmaceutical R&D back on target
Mark E. Bunnage
NATURE CHEMICAL BIOLOGY (2011)
The productivity crisis in pharmaceutical R&D
Fabio Pammolli et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Enabling future drug discovery by de novo design
Markus Hartenfeller et al.
WILEY INTERDISCIPLINARY REVIEWS-COMPUTATIONAL MOLECULAR SCIENCE (2011)
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Klaus Strebhardt
NATURE REVIEWS DRUG DISCOVERY (2010)
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Susanne M. A. Lens et al.
NATURE REVIEWS CANCER (2010)
Identification and Validation of a Potent Type II Inhibitor of Inactive Polo-like Kinase 1
Sarah Keppner et al.
CHEMMEDCHEM (2009)
Kinase-targeted libraries: The design and synthesis of novel, potent, and selective kinase inhibitors
Irini Akritopoulou-Zanze et al.
DRUG DISCOVERY TODAY (2009)
Voyages to the (un)known: adaptive design of bioactive compounds
Gisbert Schneider et al.
TRENDS IN BIOTECHNOLOGY (2009)
Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1
Anand Krishnan et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells
Andrzej Stepulak et al.
CANCER BIOLOGY & THERAPY (2008)
Structure of the catalytic domain of human polo-like kinase 1
Michael Kothe et al.
BIOCHEMISTRY (2007)
The mitsunobu reaction: Origin, mechanism, improvements, and applications
Tracy Yuen Sze But et al.
CHEMISTRY-AN ASIAN JOURNAL (2007)
Rational design of inhibitors that bind to inactive kinase conformations
Y Liu et al.
NATURE CHEMICAL BIOLOGY (2006)
SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors
NM Heron et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Computer-based de novo design of drug-like molecules
G Schneider et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Collection of bioactive reference compounds for focused library design
P Schneider et al.
QSAR & COMBINATORIAL SCIENCE (2003)
Neighborhood behavior of in silico structural spaces with respect to in vitro activity spaces - A novel understanding of the molecular similarity principle in the context of multiple receptor binding profiles
D Horvath et al.
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES (2003)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
分享论文
